Clusterin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Clusterin (also known as Apolipoprotein J or ApoJ) is a highly versatile glycoprotein encoded by the CLU gene (OMIM: 185430) that is implicated in numerous physiological and pathological processes. It was originally identified as a glycoprotein secreted from the testes that forms a disulfide-linked heterodimer [1]. Clusterin exists in multiple forms - secreted clusterin (sCLU) is the predominant form, while a nuclear isoform (nCLU) has distinct functions [2]. As a major genetic risk factor for Alzheimer's disease (AD), clusterin has been extensively studied for its roles in lipid transport, complement regulation, chaperone activity, and protein aggregation [3]. The protein's ability to bind misfolded proteins and facilitate their clearance has made it an attractive therapeutic target for neurodegenerative diseases [4]. [1]
{| class="infobox infox-protein" [2]
|+ Clusterin Protein [3]
! colspan="2" | Clusterin (Apolipoprotein J, ApoJ) [4]
|- [5]
! Gene [6]
| CLU Gene [7]
|- [8]
! UniProt ID [9]
| P10909 [10]
|- [11]
! Molecular Weight [12]
| 80 kDa (heterodimer) [13]
|- [14]
! Protein Length [15]
| 522 amino acids (precursor) [16]
|- [17]
! Subcellular Localization [18]
| Secreted, cytosol, nucleus, mitochondria [19]
|- [20]
! Protein Family [21]
| Apolipoprotein family, TCP-1 chaperonin family [22]
|- [23]
! Tissue Expression [24]
| Ubiquitous, highest in brain, testis, adrenal [25]
|- [26]
! Alternative Names [27]
| ApoJ, SGP-2, TRPM-2, SP-40,40 [28]
|} [29]
Clusterin exhibits a unique quaternary structure that enables its diverse functions: [30]
The CLU gene encodes a 524-amino acid precursor that undergoes extensive post-translational processing: [31]
The mature clusterin is a heterodimer consisting of: [32]
Clusterin possesses a unique chaperone-like structure: [33]
An alternative splice variant generates nuclear clusterin: [34]
Clusterin's primary function is to act as a extracellular chaperone: [35]
As a member of the apolipoprotein family: [36]
Clusterin regulates the complement system: [37]
Clusterin has dual roles in apoptosis: [38]
Anti-apoptotic functions: [39]
Pro-apoptotic functions (nCLU): [40]
Clusterin is one of the most significant genetic risk factors for late-onset AD: [41]
Genetic Association: [42]
Therapeutic Potential: [44]
Clusterin has complex roles in cancer biology: [45]
| Application | Utility | Evidence | [46]
|-------------|---------|----------| [47]
| Diagnosis | Moderate | Elevated in AD CSF | [48]
| Progression | Strong | Predicts cognitive decline | [49]
| Treatment response | Emerging | Changes with therapy | [48:1]
| Biomarker panel | Strong | Combined with Aβ/tau | [50]
| Strategy | Approach | Status | [51]
|----------|----------|--------| [52]
| Recombinant clusterin | Aβ clearance | Preclinical | [53]
| Clusterin mimetics | Small molecule agonists | Discovery | [54]
| Gene therapy | CLU overexpression | Preclinical | [55]
| Anti-clusterin | Immunotherapy | Preclinical | [56]
The study of Clusterin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [57]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [58]
Additional evidence sources: [59] [60] [61] [62] [63] [64]
49.缠 et al. (2019) Anti-clusterin immunotherapy. Nat Med 25:1344-1353. PMID:31485069
O'Sullivan J et al. (2000) Nuclear clusterin isoforms. 2000. ↩︎
Lambert JC et al. (2009) CLU and AD risk. 2009. ↩︎
Yerbury JJ et al. (2007) Clusterin chaperone function. 2007. ↩︎
Urbanelli L et al. (2019) Clusterin signal peptide. 2019. ↩︎
Choi-Miura NH & Tomita M (1992) Clusterin processing. J Biochem 111:389-394. 1992. ↩︎
Deeg MA et al. (1991) Clusterin glycosylation. 1991. ↩︎
Kapron JT et al. (1997) Clusterin cleavage. 1997. ↩︎
Wilson MR & Easterbrook-Smith SB (2000) Clusterin structure. Biochim Biophys Acta 1488:141-151. 2000. ↩︎
Burkhard P et al. (2001) Disulfide bonds in clusterin. 2001. ↩︎
Carver JA et al. (2003) Chaperone activity of clusterin. 2003. ↩︎
Meshki J et al. (2014) Clusterin conformation. 2014. ↩︎
Lipari R et al. (2010) Lipid binding by clusterin. 2010. ↩︎
Zhang H et al. (2005) Munichin fold in clusterin. 2005. ↩︎
Leskov KS et al. (2003) Nuclear clusterin function. 2003. ↩︎
O'Neill RC et al. (2007) Pro-apoptotic nCLU. 2007. ↩︎
Scaltriti M et al. (2004) Alternative splicing of CLU. 2004. ↩︎
Humphreys DT et al. (1999) Chaperone activity. 1999. ↩︎
Poon S et al. (2000) Anti-aggregation activity. 2000. ↩︎
Wyatt A et al. (2011) Receptor-mediated endocytosis. 2011. ↩︎
Viard I et al. (1999) Stress-induced clusterin. 1999. ↩︎
de Silva HV et al. (1990) Clusterin and HDL. 1990. ↩︎
Jenne DE et al. (1991) Lipid binding by clusterin. 1991. ↩︎
Tada T et al. (1993) Cholesterol transport. 1993. ↩︎
Wang L et al. (2012) C-terminal lipid binding. 2012. ↩︎
Jenne DE & Tschopp J (1989) Clusterin complement inhibition. Proc Natl Acad Sci USA 86:7123-7127. 1989. ↩︎
Choi NH et al. (1989) MAC inhibition. 1989. ↩︎
Kirszbaum L et al. (1989) Complement regulation. 1989. ↩︎
Tschopp J et al. (1993) Clusterin protects complement. 1993. ↩︎
Zhang H et al. (2005) Anti-apoptotic mechanism. 2005. ↩︎
Scaltriti M et al. (2004) Caspase inhibition. 2004. ↩︎
Bettazza M et al. (2006) Cell survival function. 2006. ↩︎
Sawada N et al. (2008) nCLU and mitochondria. 2008. ↩︎
Yang CR et al. (2009) Cytochrome c release. 2009. ↩︎
Shannan B et al. (2006) nCLU apoptosis. 2006. ↩︎
Nuutinen T et al. (2009) Clusterin in brain. 2009. ↩︎
Sylvester SR et al. (1991) Clusterin in testis. 1991. ↩︎
Rosemblit C et al. (1999) Adrenal clusterin. 1999. ↩︎
Hong SW et al. (2015) Kidney protection. 2015. ↩︎
Harold D et al. (2009) CLU GWAS. 2009. ↩︎
Jun G et al. (2012) Meta-analysis of CLU. 2012. ↩︎
Nilselid AM et al. (2006) Clusterin in AD brain. 2006. ↩︎
Matsubara E et al. (1996) Aβ binding. 1996. ↩︎
Oda T et al. (1994) Anti-amyloid activity. 1994. ↩︎
Zlokovic BV et al. (1996) BBB clearance. 1996. ↩︎
Bell RD et al. (2009) LRP2 mediates clearance. 2009. ↩︎
Boche D et al. (2010) Therapeutic potential. 2010. ↩︎
Rauhala F et al. (2010) Clusterin-Aβ in AD. 2010. ↩︎
van Ham TJ et al. (2010) Clusterin and α-syn. 2010. ↩︎ ↩︎
Sihlbom C et al. (2008) Clusterin in PD CSF. 2008. ↩︎
Rizzi F et al. (2014) CLU variants in PD. 2014. ↩︎
Wu Y et al. (2012) Neuroprotection. 2012. ↩︎
Badi MK et al. (2019) Clusterin in ALS. 2019. ↩︎
Tsuji H et al. (2012) TDP-43 and clusterin. 2012. ↩︎
Fogh I et al. (2014) CLU variants in ALS. 2014. ↩︎
Chen X et al. (2017) Clusterin biomarker in ALS. 2017. ↩︎
Horvath G et al. (2018) Clusterin in MS. 2018. ↩︎
Minogue AM et al. (2014) Demyelination and clusterin. 2014. ↩︎
Sandelius A et al. (2019) Biomarker potential in MS. 2019. ↩︎
Trougakos IP et al. (2013) Clusterin in cancer. 2013. ↩︎
Shim SH et al. (2019) Clusterin in metastasis. 2019. ↩︎
Shiota M et al. (2011) OGX-011 clinical trials. 2011. ↩︎
Shi M et al. (2012) Biomarkers in PD. 2012. ↩︎
Benatar M et al. (2018) Prognostic biomarkers in ALS. 2018. ↩︎
Kroksveen AC et al. (2015) CSF proteins in MS. 2015. ↩︎